Effective therapies for sickle cell disease: are we there yet?
Sickle cell disease (SCD) is a common genetic blood disorder associated with acute and chronic pain, progressive multiorgan damage, and early mortality. Recent advances in technologies to manipulate the human genome, a century of research and the development of techniques enabling the isolation, eff...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Crossley, Merlin [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2022transfer abstract |
|---|
| Umfang: |
15 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Degrading chlorinated aliphatics by reductive dechlorination of groundwater samples from the Santa Susana Field Laboratory - Dutta, Nalok ELSEVIER, 2022, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:38 ; year:2022 ; number:12 ; pages:1284-1298 ; extent:15 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.tig.2022.07.003 |
|---|
| Katalog-ID: |
ELV05948599X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV05948599X | ||
| 003 | DE-627 | ||
| 005 | 20230626052958.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 221219s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.tig.2022.07.003 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001965.pica |
| 035 | |a (DE-627)ELV05948599X | ||
| 035 | |a (ELSEVIER)S0168-9525(22)00180-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 333.7 |q VZ |
| 084 | |a 43.00 |2 bkl | ||
| 100 | 1 | |a Crossley, Merlin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effective therapies for sickle cell disease: are we there yet? |
| 264 | 1 | |c 2022transfer abstract | |
| 300 | |a 15 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Sickle cell disease (SCD) is a common genetic blood disorder associated with acute and chronic pain, progressive multiorgan damage, and early mortality. Recent advances in technologies to manipulate the human genome, a century of research and the development of techniques enabling the isolation, efficient genetic modification, and reimplantation of autologous patient hematopoietic stem cells (HSCs), mean that curing most patients with SCD could soon be a reality in wealthy countries. In parallel, ongoing research is pursuing more facile treatments, such as in-vivo-delivered genetic therapies and new drugs that can eventually be administered in low- and middle-income countries where most SCD patients reside. | ||
| 520 | |a Sickle cell disease (SCD) is a common genetic blood disorder associated with acute and chronic pain, progressive multiorgan damage, and early mortality. Recent advances in technologies to manipulate the human genome, a century of research and the development of techniques enabling the isolation, efficient genetic modification, and reimplantation of autologous patient hematopoietic stem cells (HSCs), mean that curing most patients with SCD could soon be a reality in wealthy countries. In parallel, ongoing research is pursuing more facile treatments, such as in-vivo-delivered genetic therapies and new drugs that can eventually be administered in low- and middle-income countries where most SCD patients reside. | ||
| 700 | 1 | |a Christakopoulos, Georgios E. |4 oth | |
| 700 | 1 | |a Weiss, Mitchell J. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Dutta, Nalok ELSEVIER |t Degrading chlorinated aliphatics by reductive dechlorination of groundwater samples from the Santa Susana Field Laboratory |d 2022 |g Amsterdam [u.a.] |w (DE-627)ELV00781545X |
| 773 | 1 | 8 | |g volume:38 |g year:2022 |g number:12 |g pages:1284-1298 |g extent:15 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.tig.2022.07.003 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-GGO | ||
| 936 | b | k | |a 43.00 |j Umweltforschung |j Umweltschutz: Allgemeines |q VZ |
| 951 | |a AR | ||
| 952 | |d 38 |j 2022 |e 12 |h 1284-1298 |g 15 | ||
| author_variant |
m c mc |
|---|---|
| matchkey_str |
crossleymerlinchristakopoulosgeorgiosewe:2022----:fetvteaisosclcldsa |
| hierarchy_sort_str |
2022transfer abstract |
| bklnumber |
43.00 |
| publishDate |
2022 |
| allfields |
10.1016/j.tig.2022.07.003 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001965.pica (DE-627)ELV05948599X (ELSEVIER)S0168-9525(22)00180-9 DE-627 ger DE-627 rakwb eng 333.7 VZ 43.00 bkl Crossley, Merlin verfasserin aut Effective therapies for sickle cell disease: are we there yet? 2022transfer abstract 15 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Sickle cell disease (SCD) is a common genetic blood disorder associated with acute and chronic pain, progressive multiorgan damage, and early mortality. Recent advances in technologies to manipulate the human genome, a century of research and the development of techniques enabling the isolation, efficient genetic modification, and reimplantation of autologous patient hematopoietic stem cells (HSCs), mean that curing most patients with SCD could soon be a reality in wealthy countries. In parallel, ongoing research is pursuing more facile treatments, such as in-vivo-delivered genetic therapies and new drugs that can eventually be administered in low- and middle-income countries where most SCD patients reside. Sickle cell disease (SCD) is a common genetic blood disorder associated with acute and chronic pain, progressive multiorgan damage, and early mortality. Recent advances in technologies to manipulate the human genome, a century of research and the development of techniques enabling the isolation, efficient genetic modification, and reimplantation of autologous patient hematopoietic stem cells (HSCs), mean that curing most patients with SCD could soon be a reality in wealthy countries. In parallel, ongoing research is pursuing more facile treatments, such as in-vivo-delivered genetic therapies and new drugs that can eventually be administered in low- and middle-income countries where most SCD patients reside. Christakopoulos, Georgios E. oth Weiss, Mitchell J. oth Enthalten in Elsevier Science Dutta, Nalok ELSEVIER Degrading chlorinated aliphatics by reductive dechlorination of groundwater samples from the Santa Susana Field Laboratory 2022 Amsterdam [u.a.] (DE-627)ELV00781545X volume:38 year:2022 number:12 pages:1284-1298 extent:15 https://doi.org/10.1016/j.tig.2022.07.003 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA SSG-OPC-GGO 43.00 Umweltforschung Umweltschutz: Allgemeines VZ AR 38 2022 12 1284-1298 15 |
| spelling |
10.1016/j.tig.2022.07.003 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001965.pica (DE-627)ELV05948599X (ELSEVIER)S0168-9525(22)00180-9 DE-627 ger DE-627 rakwb eng 333.7 VZ 43.00 bkl Crossley, Merlin verfasserin aut Effective therapies for sickle cell disease: are we there yet? 2022transfer abstract 15 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Sickle cell disease (SCD) is a common genetic blood disorder associated with acute and chronic pain, progressive multiorgan damage, and early mortality. Recent advances in technologies to manipulate the human genome, a century of research and the development of techniques enabling the isolation, efficient genetic modification, and reimplantation of autologous patient hematopoietic stem cells (HSCs), mean that curing most patients with SCD could soon be a reality in wealthy countries. In parallel, ongoing research is pursuing more facile treatments, such as in-vivo-delivered genetic therapies and new drugs that can eventually be administered in low- and middle-income countries where most SCD patients reside. Sickle cell disease (SCD) is a common genetic blood disorder associated with acute and chronic pain, progressive multiorgan damage, and early mortality. Recent advances in technologies to manipulate the human genome, a century of research and the development of techniques enabling the isolation, efficient genetic modification, and reimplantation of autologous patient hematopoietic stem cells (HSCs), mean that curing most patients with SCD could soon be a reality in wealthy countries. In parallel, ongoing research is pursuing more facile treatments, such as in-vivo-delivered genetic therapies and new drugs that can eventually be administered in low- and middle-income countries where most SCD patients reside. Christakopoulos, Georgios E. oth Weiss, Mitchell J. oth Enthalten in Elsevier Science Dutta, Nalok ELSEVIER Degrading chlorinated aliphatics by reductive dechlorination of groundwater samples from the Santa Susana Field Laboratory 2022 Amsterdam [u.a.] (DE-627)ELV00781545X volume:38 year:2022 number:12 pages:1284-1298 extent:15 https://doi.org/10.1016/j.tig.2022.07.003 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA SSG-OPC-GGO 43.00 Umweltforschung Umweltschutz: Allgemeines VZ AR 38 2022 12 1284-1298 15 |
| allfields_unstemmed |
10.1016/j.tig.2022.07.003 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001965.pica (DE-627)ELV05948599X (ELSEVIER)S0168-9525(22)00180-9 DE-627 ger DE-627 rakwb eng 333.7 VZ 43.00 bkl Crossley, Merlin verfasserin aut Effective therapies for sickle cell disease: are we there yet? 2022transfer abstract 15 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Sickle cell disease (SCD) is a common genetic blood disorder associated with acute and chronic pain, progressive multiorgan damage, and early mortality. Recent advances in technologies to manipulate the human genome, a century of research and the development of techniques enabling the isolation, efficient genetic modification, and reimplantation of autologous patient hematopoietic stem cells (HSCs), mean that curing most patients with SCD could soon be a reality in wealthy countries. In parallel, ongoing research is pursuing more facile treatments, such as in-vivo-delivered genetic therapies and new drugs that can eventually be administered in low- and middle-income countries where most SCD patients reside. Sickle cell disease (SCD) is a common genetic blood disorder associated with acute and chronic pain, progressive multiorgan damage, and early mortality. Recent advances in technologies to manipulate the human genome, a century of research and the development of techniques enabling the isolation, efficient genetic modification, and reimplantation of autologous patient hematopoietic stem cells (HSCs), mean that curing most patients with SCD could soon be a reality in wealthy countries. In parallel, ongoing research is pursuing more facile treatments, such as in-vivo-delivered genetic therapies and new drugs that can eventually be administered in low- and middle-income countries where most SCD patients reside. Christakopoulos, Georgios E. oth Weiss, Mitchell J. oth Enthalten in Elsevier Science Dutta, Nalok ELSEVIER Degrading chlorinated aliphatics by reductive dechlorination of groundwater samples from the Santa Susana Field Laboratory 2022 Amsterdam [u.a.] (DE-627)ELV00781545X volume:38 year:2022 number:12 pages:1284-1298 extent:15 https://doi.org/10.1016/j.tig.2022.07.003 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA SSG-OPC-GGO 43.00 Umweltforschung Umweltschutz: Allgemeines VZ AR 38 2022 12 1284-1298 15 |
| allfieldsGer |
10.1016/j.tig.2022.07.003 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001965.pica (DE-627)ELV05948599X (ELSEVIER)S0168-9525(22)00180-9 DE-627 ger DE-627 rakwb eng 333.7 VZ 43.00 bkl Crossley, Merlin verfasserin aut Effective therapies for sickle cell disease: are we there yet? 2022transfer abstract 15 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Sickle cell disease (SCD) is a common genetic blood disorder associated with acute and chronic pain, progressive multiorgan damage, and early mortality. Recent advances in technologies to manipulate the human genome, a century of research and the development of techniques enabling the isolation, efficient genetic modification, and reimplantation of autologous patient hematopoietic stem cells (HSCs), mean that curing most patients with SCD could soon be a reality in wealthy countries. In parallel, ongoing research is pursuing more facile treatments, such as in-vivo-delivered genetic therapies and new drugs that can eventually be administered in low- and middle-income countries where most SCD patients reside. Sickle cell disease (SCD) is a common genetic blood disorder associated with acute and chronic pain, progressive multiorgan damage, and early mortality. Recent advances in technologies to manipulate the human genome, a century of research and the development of techniques enabling the isolation, efficient genetic modification, and reimplantation of autologous patient hematopoietic stem cells (HSCs), mean that curing most patients with SCD could soon be a reality in wealthy countries. In parallel, ongoing research is pursuing more facile treatments, such as in-vivo-delivered genetic therapies and new drugs that can eventually be administered in low- and middle-income countries where most SCD patients reside. Christakopoulos, Georgios E. oth Weiss, Mitchell J. oth Enthalten in Elsevier Science Dutta, Nalok ELSEVIER Degrading chlorinated aliphatics by reductive dechlorination of groundwater samples from the Santa Susana Field Laboratory 2022 Amsterdam [u.a.] (DE-627)ELV00781545X volume:38 year:2022 number:12 pages:1284-1298 extent:15 https://doi.org/10.1016/j.tig.2022.07.003 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA SSG-OPC-GGO 43.00 Umweltforschung Umweltschutz: Allgemeines VZ AR 38 2022 12 1284-1298 15 |
| allfieldsSound |
10.1016/j.tig.2022.07.003 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001965.pica (DE-627)ELV05948599X (ELSEVIER)S0168-9525(22)00180-9 DE-627 ger DE-627 rakwb eng 333.7 VZ 43.00 bkl Crossley, Merlin verfasserin aut Effective therapies for sickle cell disease: are we there yet? 2022transfer abstract 15 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Sickle cell disease (SCD) is a common genetic blood disorder associated with acute and chronic pain, progressive multiorgan damage, and early mortality. Recent advances in technologies to manipulate the human genome, a century of research and the development of techniques enabling the isolation, efficient genetic modification, and reimplantation of autologous patient hematopoietic stem cells (HSCs), mean that curing most patients with SCD could soon be a reality in wealthy countries. In parallel, ongoing research is pursuing more facile treatments, such as in-vivo-delivered genetic therapies and new drugs that can eventually be administered in low- and middle-income countries where most SCD patients reside. Sickle cell disease (SCD) is a common genetic blood disorder associated with acute and chronic pain, progressive multiorgan damage, and early mortality. Recent advances in technologies to manipulate the human genome, a century of research and the development of techniques enabling the isolation, efficient genetic modification, and reimplantation of autologous patient hematopoietic stem cells (HSCs), mean that curing most patients with SCD could soon be a reality in wealthy countries. In parallel, ongoing research is pursuing more facile treatments, such as in-vivo-delivered genetic therapies and new drugs that can eventually be administered in low- and middle-income countries where most SCD patients reside. Christakopoulos, Georgios E. oth Weiss, Mitchell J. oth Enthalten in Elsevier Science Dutta, Nalok ELSEVIER Degrading chlorinated aliphatics by reductive dechlorination of groundwater samples from the Santa Susana Field Laboratory 2022 Amsterdam [u.a.] (DE-627)ELV00781545X volume:38 year:2022 number:12 pages:1284-1298 extent:15 https://doi.org/10.1016/j.tig.2022.07.003 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA SSG-OPC-GGO 43.00 Umweltforschung Umweltschutz: Allgemeines VZ AR 38 2022 12 1284-1298 15 |
| language |
English |
| source |
Enthalten in Degrading chlorinated aliphatics by reductive dechlorination of groundwater samples from the Santa Susana Field Laboratory Amsterdam [u.a.] volume:38 year:2022 number:12 pages:1284-1298 extent:15 |
| sourceStr |
Enthalten in Degrading chlorinated aliphatics by reductive dechlorination of groundwater samples from the Santa Susana Field Laboratory Amsterdam [u.a.] volume:38 year:2022 number:12 pages:1284-1298 extent:15 |
| format_phy_str_mv |
Article |
| bklname |
Umweltforschung Umweltschutz: Allgemeines |
| institution |
findex.gbv.de |
| dewey-raw |
333.7 |
| isfreeaccess_bool |
false |
| container_title |
Degrading chlorinated aliphatics by reductive dechlorination of groundwater samples from the Santa Susana Field Laboratory |
| authorswithroles_txt_mv |
Crossley, Merlin @@aut@@ Christakopoulos, Georgios E. @@oth@@ Weiss, Mitchell J. @@oth@@ |
| publishDateDaySort_date |
2022-01-01T00:00:00Z |
| hierarchy_top_id |
ELV00781545X |
| dewey-sort |
3333.7 |
| id |
ELV05948599X |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV05948599X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626052958.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">221219s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.tig.2022.07.003</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001965.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV05948599X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0168-9525(22)00180-9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">333.7</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">43.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Crossley, Merlin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Effective therapies for sickle cell disease: are we there yet?</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">15</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Sickle cell disease (SCD) is a common genetic blood disorder associated with acute and chronic pain, progressive multiorgan damage, and early mortality. Recent advances in technologies to manipulate the human genome, a century of research and the development of techniques enabling the isolation, efficient genetic modification, and reimplantation of autologous patient hematopoietic stem cells (HSCs), mean that curing most patients with SCD could soon be a reality in wealthy countries. In parallel, ongoing research is pursuing more facile treatments, such as in-vivo-delivered genetic therapies and new drugs that can eventually be administered in low- and middle-income countries where most SCD patients reside.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Sickle cell disease (SCD) is a common genetic blood disorder associated with acute and chronic pain, progressive multiorgan damage, and early mortality. Recent advances in technologies to manipulate the human genome, a century of research and the development of techniques enabling the isolation, efficient genetic modification, and reimplantation of autologous patient hematopoietic stem cells (HSCs), mean that curing most patients with SCD could soon be a reality in wealthy countries. In parallel, ongoing research is pursuing more facile treatments, such as in-vivo-delivered genetic therapies and new drugs that can eventually be administered in low- and middle-income countries where most SCD patients reside.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Christakopoulos, Georgios E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Weiss, Mitchell J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Dutta, Nalok ELSEVIER</subfield><subfield code="t">Degrading chlorinated aliphatics by reductive dechlorination of groundwater samples from the Santa Susana Field Laboratory</subfield><subfield code="d">2022</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV00781545X</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:38</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:12</subfield><subfield code="g">pages:1284-1298</subfield><subfield code="g">extent:15</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.tig.2022.07.003</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-GGO</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">43.00</subfield><subfield code="j">Umweltforschung</subfield><subfield code="j">Umweltschutz: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">38</subfield><subfield code="j">2022</subfield><subfield code="e">12</subfield><subfield code="h">1284-1298</subfield><subfield code="g">15</subfield></datafield></record></collection>
|
| author |
Crossley, Merlin |
| spellingShingle |
Crossley, Merlin ddc 333.7 bkl 43.00 Effective therapies for sickle cell disease: are we there yet? |
| authorStr |
Crossley, Merlin |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV00781545X |
| format |
electronic Article |
| dewey-ones |
333 - Economics of land & energy |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
333.7 VZ 43.00 bkl Effective therapies for sickle cell disease: are we there yet? |
| topic |
ddc 333.7 bkl 43.00 |
| topic_unstemmed |
ddc 333.7 bkl 43.00 |
| topic_browse |
ddc 333.7 bkl 43.00 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
g e c ge gec m j w mj mjw |
| hierarchy_parent_title |
Degrading chlorinated aliphatics by reductive dechlorination of groundwater samples from the Santa Susana Field Laboratory |
| hierarchy_parent_id |
ELV00781545X |
| dewey-tens |
330 - Economics |
| hierarchy_top_title |
Degrading chlorinated aliphatics by reductive dechlorination of groundwater samples from the Santa Susana Field Laboratory |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV00781545X |
| title |
Effective therapies for sickle cell disease: are we there yet? |
| ctrlnum |
(DE-627)ELV05948599X (ELSEVIER)S0168-9525(22)00180-9 |
| title_full |
Effective therapies for sickle cell disease: are we there yet? |
| author_sort |
Crossley, Merlin |
| journal |
Degrading chlorinated aliphatics by reductive dechlorination of groundwater samples from the Santa Susana Field Laboratory |
| journalStr |
Degrading chlorinated aliphatics by reductive dechlorination of groundwater samples from the Santa Susana Field Laboratory |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
300 - Social sciences |
| recordtype |
marc |
| publishDateSort |
2022 |
| contenttype_str_mv |
zzz |
| container_start_page |
1284 |
| author_browse |
Crossley, Merlin |
| container_volume |
38 |
| physical |
15 |
| class |
333.7 VZ 43.00 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Crossley, Merlin |
| doi_str_mv |
10.1016/j.tig.2022.07.003 |
| dewey-full |
333.7 |
| title_sort |
effective therapies for sickle cell disease: are we there yet? |
| title_auth |
Effective therapies for sickle cell disease: are we there yet? |
| abstract |
Sickle cell disease (SCD) is a common genetic blood disorder associated with acute and chronic pain, progressive multiorgan damage, and early mortality. Recent advances in technologies to manipulate the human genome, a century of research and the development of techniques enabling the isolation, efficient genetic modification, and reimplantation of autologous patient hematopoietic stem cells (HSCs), mean that curing most patients with SCD could soon be a reality in wealthy countries. In parallel, ongoing research is pursuing more facile treatments, such as in-vivo-delivered genetic therapies and new drugs that can eventually be administered in low- and middle-income countries where most SCD patients reside. |
| abstractGer |
Sickle cell disease (SCD) is a common genetic blood disorder associated with acute and chronic pain, progressive multiorgan damage, and early mortality. Recent advances in technologies to manipulate the human genome, a century of research and the development of techniques enabling the isolation, efficient genetic modification, and reimplantation of autologous patient hematopoietic stem cells (HSCs), mean that curing most patients with SCD could soon be a reality in wealthy countries. In parallel, ongoing research is pursuing more facile treatments, such as in-vivo-delivered genetic therapies and new drugs that can eventually be administered in low- and middle-income countries where most SCD patients reside. |
| abstract_unstemmed |
Sickle cell disease (SCD) is a common genetic blood disorder associated with acute and chronic pain, progressive multiorgan damage, and early mortality. Recent advances in technologies to manipulate the human genome, a century of research and the development of techniques enabling the isolation, efficient genetic modification, and reimplantation of autologous patient hematopoietic stem cells (HSCs), mean that curing most patients with SCD could soon be a reality in wealthy countries. In parallel, ongoing research is pursuing more facile treatments, such as in-vivo-delivered genetic therapies and new drugs that can eventually be administered in low- and middle-income countries where most SCD patients reside. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA SSG-OPC-GGO |
| container_issue |
12 |
| title_short |
Effective therapies for sickle cell disease: are we there yet? |
| url |
https://doi.org/10.1016/j.tig.2022.07.003 |
| remote_bool |
true |
| author2 |
Christakopoulos, Georgios E. Weiss, Mitchell J. |
| author2Str |
Christakopoulos, Georgios E. Weiss, Mitchell J. |
| ppnlink |
ELV00781545X |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth |
| doi_str |
10.1016/j.tig.2022.07.003 |
| up_date |
2024-07-06T22:08:37.317Z |
| _version_ |
1803869190690439168 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV05948599X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626052958.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">221219s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.tig.2022.07.003</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001965.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV05948599X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0168-9525(22)00180-9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">333.7</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">43.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Crossley, Merlin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Effective therapies for sickle cell disease: are we there yet?</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">15</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Sickle cell disease (SCD) is a common genetic blood disorder associated with acute and chronic pain, progressive multiorgan damage, and early mortality. Recent advances in technologies to manipulate the human genome, a century of research and the development of techniques enabling the isolation, efficient genetic modification, and reimplantation of autologous patient hematopoietic stem cells (HSCs), mean that curing most patients with SCD could soon be a reality in wealthy countries. In parallel, ongoing research is pursuing more facile treatments, such as in-vivo-delivered genetic therapies and new drugs that can eventually be administered in low- and middle-income countries where most SCD patients reside.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Sickle cell disease (SCD) is a common genetic blood disorder associated with acute and chronic pain, progressive multiorgan damage, and early mortality. Recent advances in technologies to manipulate the human genome, a century of research and the development of techniques enabling the isolation, efficient genetic modification, and reimplantation of autologous patient hematopoietic stem cells (HSCs), mean that curing most patients with SCD could soon be a reality in wealthy countries. In parallel, ongoing research is pursuing more facile treatments, such as in-vivo-delivered genetic therapies and new drugs that can eventually be administered in low- and middle-income countries where most SCD patients reside.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Christakopoulos, Georgios E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Weiss, Mitchell J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Dutta, Nalok ELSEVIER</subfield><subfield code="t">Degrading chlorinated aliphatics by reductive dechlorination of groundwater samples from the Santa Susana Field Laboratory</subfield><subfield code="d">2022</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV00781545X</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:38</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:12</subfield><subfield code="g">pages:1284-1298</subfield><subfield code="g">extent:15</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.tig.2022.07.003</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-GGO</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">43.00</subfield><subfield code="j">Umweltforschung</subfield><subfield code="j">Umweltschutz: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">38</subfield><subfield code="j">2022</subfield><subfield code="e">12</subfield><subfield code="h">1284-1298</subfield><subfield code="g">15</subfield></datafield></record></collection>
|
| score |
7.3995256 |